2-Jul-2026
BioNTech has reportedly contacted buyers over plans to exit German sites
Seeking Alpha News (Sat, 4-Jul 11:52 AM ET)
Most and least shorted mid- to mega-cap healthcare stocks at the end of June
Seeking Alpha News (Wed, 1-Jul 10:05 AM ET)
RFK Jr. ends Emergency Use Authorizations for COVID-19 drugs
Seeking Alpha News (Tue, 30-Jun 2:30 PM ET)
BioNTech Expands Its Oncology Pipeline: How mRNA and Precision Medicine Are Changing Cancer Care
Market Chameleon (Fri, 26-Jun 4:16 AM ET)
The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
Globe Newswire (Thu, 25-Jun 11:39 AM ET)
The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
Globe Newswire (Wed, 3-Jun 9:28 AM ET)
Globe Newswire (Sat, 30-May 2:15 PM ET)
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
Globe Newswire (Fri, 22-May 5:00 AM ET)
BioNTech Shareholders Back Strong Pipeline Strategy and Board Expansion at 2026 AGM
Market Chameleon (Mon, 18-May 3:30 AM ET)
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Globe Newswire (Fri, 15-May 4:15 PM ET)
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Biontech Se - American Depositary Shares trades on the NASDAQ stock market under the symbol BNTX.
As of July 2, 2026, BNTX stock price climbed to $97.54 with 1,338,684 million shares trading.
BNTX has a beta of 1.55, meaning it tends to be more sensitive to market movements. BNTX has a correlation of 0.23 to the broad based SPY ETF.
BNTX has a market cap of $24.67 billion. This is considered a Large Cap stock.
Last quarter Biontech Se - American Depositary Shares reported $138 million in Revenue and -$2.28 earnings per share. This fell short of revenue expectation by $-77 million and exceeded earnings estimates by $.24.
In the last 3 years, BNTX traded as high as $131.49 and as low as $76.53.
The top ETF exchange traded funds that BNTX belongs to (by Net Assets): FBT, IBB, FNDF, ARKG, SPDW.
BNTX has underperformed the market in the last year with a return of -9.9%, while the SPY ETF gained +21.3%. In the last 3 month period, BNTX fell short of the market, returning +7.0%, while SPY returned +13.9%. However, in the most recent 2 weeks BNTX has outperformed the stock market by returning +7.3%, while SPY returned -0.3%.
BNTX support price is $92.12 and resistance is $95.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTX shares will trade within this expected range on the day.